The historical data trend for TG Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NKB2 vs HALO, KYMR, PCVX: Buyback Yield % Comparison
For the Biotechnology subindustry, TG Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TG Therapeutics (FRA:NKB2) has a Buyback Yield % of 2.12 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on TG Therapeutics and its competitors. According to the industry distribution chart, TG Therapeutics ranks #25 out of 742 companies in the Biotechnology industry, placing it in the top 3.4%.
Is TG Therapeutics' Buyback Yield % too high?
TG Therapeutics' current Buyback Yield % is 2.12. Based on the distribution chart, TG Therapeutics ranks #25 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TG Therapeutics has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Buyback Yield % compare to HALO and KYMR?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #25 out of 742 companies for Buyback Yield %. This places TG Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Buyback Yield % is 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €48.73, compared to a current price of €51.00 — trading 4.7% above its estimated fair value. The current Buyback Yield % is 2.12. TG Therapeutics' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Buyback Yield % is 2.12 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be overvalued.
The current stock price of €51.00 is trading 4.7% above its estimated GF Value™ of €48.73.
GuruFocus considers TG Therapeutics to be Fairly Valued.
Key valuation signals for FRA:NKB2:
Buyback Yield %: 2.12
GF Value™: €48.73 vs. price of €51.00 (4.7% above fair value)
No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
81GF Score
Get the complete analysis for FRA:NKB2
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NKB2 has been successfully added to your 
